Glix MR 60 Tablet contains Gliclazide 60 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Glix MR 60 is formulated as a modified-release tablet, allowing for a sustained and controlled release of the active ingredient, which helps maintain stable blood glucose levels over an extended period and reduces the frequency of dosing. This medication is typically prescribed as part of a comprehensive diabetes management plan that includes diet, exercise, and regular blood glucose monitoring. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to sulfonylureas. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and allergic reactions. Dose adjustments may be necessary in elderly patients or those with renal dysfunction. Glix MR 60 should be used under medical supervision with regular monitoring of blood glucose and HbA1c levels to optimize therapeutic outcomes and minimize risks. Patients are advised to adhere strictly to prescribed dosing schedules and report any signs of hypoglycemia promptly.